📰 Priority Review News
Page 104 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
June 8, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
June 7, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
June 7, 2022
/PRNewswire/ -- scentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and...
June 7, 2022
/PRNewswire/ -- MAPS Public Benefit Corporation (MAPS PBC) today announced the appointment of Jeff George and Dan Grossman, Ph.D., to serve on its Board of...
June 7, 2022
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
June 7, 2022
Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and...
June 7, 2022
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is the first and only biologic medicine approved
June 7, 2022
Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and...
June 7, 2022
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors - read this article along with other careers information, tips and advice on BioSpace
June 7, 2022
 FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is...